Thromboembolic events during treatment with thalidomide

Blood. 2002 Jun 1;99(11):4247-8. doi: 10.1182/blood-2001-12-0245.
No abstract available

Publication types

  • Clinical Trial
  • Clinical Trial, Phase II
  • Letter

MeSH terms

  • Angiogenesis Inhibitors / adverse effects*
  • Antibodies, Monoclonal / administration & dosage
  • Antibodies, Monoclonal, Murine-Derived
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Cisplatin / administration & dosage
  • Cyclophosphamide / administration & dosage
  • Dexamethasone / administration & dosage
  • Doxorubicin / administration & dosage
  • Etoposide / administration & dosage
  • Humans
  • Lymphoma, Mantle-Cell / drug therapy
  • Multiple Myeloma / drug therapy*
  • Prednisone / administration & dosage
  • Rituximab
  • Thalidomide / adverse effects*
  • Thromboembolism / chemically induced*
  • Thromboembolism / drug therapy
  • Vincristine / administration & dosage

Substances

  • Angiogenesis Inhibitors
  • Antibodies, Monoclonal
  • Antibodies, Monoclonal, Murine-Derived
  • Rituximab
  • Thalidomide
  • Vincristine
  • Etoposide
  • Dexamethasone
  • Doxorubicin
  • Cyclophosphamide
  • Cisplatin
  • Prednisone

Supplementary concepts

  • CHOP protocol